All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Global Portal were delighted to speak to Guy Sauvageau, Maisonneuve-Rosemont Hospital, Montreal, CA, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Guy Sauvageau: Why should we target RUNX1 in AML treatment?
Guy Sauvageau explains targeting RUNX1 in AML treatment. He explains different subsets of genetic mutations confer different treatment response and discusses his work in identifying small molecule compounds that aims to reinstate sensitivity to treatment in a specific subset of AML.
Why should we target RUNX1 in AML treatment?
How should family members with familial RUNX1 germline mutations be monitored?
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Jane Churpek, The University of Wisconsin,...
ESH 2019 | Is AML susceptible to immunotherapy?
John DiPersio outlines the current challenges of immunotherapeutic approaches in AML, such as lack of selective targets and life-threatening side-effects, and how they can potentially be overcome.
Subscribe to get the best content related to AML delivered to your inbox